TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03325777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Approach Bias Retraining
Description: The Approach Avoidance Task (AAT) used for this experiment is an implicit, computerized paradigm in which participants respond to visually presented pictures on a computer screen displaying either 1) smoking-related images or 2) positive images, by pulling a joystick either towards their body (approach movement) or pushing it away from their body (avoidance movement). By pulling the joystick towards their body, the picture grows in size; by pushing the joystick away, the picture shrinks and then disappears from the screen. Participants are instructed to pull upon seeing an image tilted to the right and to push upon seeing a left-tilt image, while ignoring the image content and responding as quickly and as accurately as possible.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: SHAM Training
Description: SHAM Training
Study: NCT01238536

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural steroid with local anesthetic injection
Description: Epidural steroid injectate will be 2cc of 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural local anesthetic injection
Description: Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural steroid injection
Description: Epidural steroid injectate will be 2cc of .25 - 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural local anesthetic injection
Description: Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
Study: NCT03482752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molgramostim
Description: 300 µg inhaled molgramostim in cycles of once daily administration for 7 days, then 7 days off treatment.
Study: NCT01883284

Intervention type: OTHER
Group type: OTHER
Intervention: Tests in vitro after sampling nasal cells of CF patients or controls
Description: Nasal cells of CF patients or controls were collected by scratching of intermediate turbinate and cultured in vitro. Epigenetic modifiers treatment was applied to these ex vivo nasal epithelia. Then, mRNA, protein and secretions were quantified.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tests in vitro after sampling nasal cells of CF patients or controls
Description: Nasal cells of CF patients or controls were collected by scratching of intermediate turbinate and cultured in vitro. Epigenetic modifiers treatment was applied to these ex vivo nasal epithelia. Then, mRNA, protein and secretions were quantified.
Study: NCT04467892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: received high dose (30 mg/kg) methylprednisolone slowly intravenous in 250 ml normal saline every 8 hours for only 4 days
Study: NCT04467892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methyl Prednisolonate
Description: received 1 mg/kg/day methylprednisolone divided to three doses given every 8 hours for two weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ventilators
Description: all patients in both groups will be ventilated with CMV for 2 weeks
Study: NCT03251482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg
Description: Apixaban 2.5 mg administered orally twice a day for 10 to 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg
Description: Apixaban 2.5 mg administered orally twice a day for 10 to 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg
Description: Apixaban 2.5 mg administered orally twice a day for 10 to 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg
Description: Apixaban 2.5 mg administered orally twice a day for 10 to 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg
Description: Apixaban 2.5 mg administered orally twice a day for 10 to 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg
Description: Apixaban 2.5 mg administered orally twice a day for 10 to 14 days.
Study: NCT02889146

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Control group will receive respiratory therapy according to the service routine and conventional physical therapy. Conventional physical therapy will be offered by the hospital physical therapists, according to their own criteria. Consists of passive, assisted and resisted mobilization, positioning in bed, transferring to bedside or chair, orthostatism and deambulation, however without a definition of a protocol. The physical therapist will be responsible for the choice of the techniques employed in each session. There will be no previous definition of the next sessions. No technology equipment will be used in this group, since they are not available in the routine care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early and progressive mobilization program
Description: Protocol group will receive respiratory therapy according to the service routine and motor physical therapy according to the program of early and progressive mobilization. Patients will receive the program once daily during the intensive care unit stay, offered by a trained physical therapist, at the adequate level according to the level of consciousness and muscle strength. The program contains by techniques for muscle length and muscle strength maintenance or gain, aerobic exercises, exercises for gait rehabilitation and cognitive components. Patient will progress to the next level of the protocol completing the previous level. Technology equipment available: functional electrical stimulation device, dumbbells, cycle ergometer, fixed walker, ambulation assistive device and video game.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory therapy
Description: Respiratory therapy according to the service routine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory therapy
Description: Respiratory therapy according to the service routine.
Study: NCT03147976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 337
Description: 6-{(1R)-1-\[8-fluoro-6-(1-methyl-1H-pyrazol-4- yl)\[1,2,4\]triazolo\[4,3-a\]pyridin-3-yl\]ethyl}-3-(2- methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
Study: NCT02447328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: fulvestrant (Faslodex®) 500mg/month for about 6 months with an additional 500mg dose given 14 days after the initial dose injection.
Study: NCT02995629

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser indirect ophthalmoscopy pan retinal photocoagulation
Description: * Prior to procedure, eligible patient is dilated and a topical anesthesia is administered 3 to 5 minutes prior to treatment initiation~* Treatment duration is fixed at 50 minutes and power is titrated until moderate gray-white burns are achieved, avoiding long ciliary nerves~* Target treatment of 250 spots~* Only one eye per eligible patient randomized with regard to whether green or yellow laser utilized first~* After treatment,pain assessment conducted:spot count, laser parameters and treatment duration recorded for each respective laser wavelength

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser indirect ophthalmoscopy pan retinal photocoagulation
Description: * Prior to procedure, eligible patient is dilated and a topical anesthesia is administered 3 to 5 minutes prior to treatment initiation~* Treatment duration is fixed at 50 minutes and power is titrated until moderate gray-white burns are achieved, avoiding long ciliary nerves~* Target treatment of 250 spots~* Only one eye per eligible patient randomized with regard to whether green or yellow laser utilized first~* After treatment,pain assessment conducted:spot count, laser parameters and treatment duration recorded for each respective laser wavelength
Study: NCT03015194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN 3 transcatheter heart valve
Description: Used to relieve aortic stenosis in patients with symptomatic heart disease~In this study it is not used for aortic stenosis-----the device is used in the mitral valve position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASHI INTECC Astato XS 20
Description: The Astato 0.014 guidewire is used for transcatheter electrosurgery in two steps in this procedure. First it is used for leaflet traversal during electrification. This procedure is similar to the use of the Astato XS20 and an amputated Asahi Confienza Pro 12 in the transcaval IDE investigation recently published. Second, the midshaft is focally denuded and electrified for the leaflet traversal step.
Study: NCT01537991

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All patients will receive radiotherapy to the primary lung tumour and any demonstrated nodal involvement. Patients will be given radiotherapy of a dose between 58 and 65Gy in 20 fractions. Dose will be determined by the patients' group.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All patients will receive radiotherapy to the primary lung tumour and any demonstrated nodal involvement. Patients will be given radiotherapy of a dose between 58 and 65Gy in 20 fractions. Dose will be determined by the patients' group.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All patients will receive radiotherapy to the primary lung tumour and any demonstrated nodal involvement. Patients will be given radiotherapy of a dose between 58 and 65Gy in 20 fractions. Dose will be determined by the patients' group.
Study: NCT01504191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based CBT
Description: The participants read texts and do weekly homework assignments instructed from an Internet page. Additional resources like discussion forum, pictures, animations, videos and sounds will be a part of the treatment program.~A psychologist will communicate with the participants through internal text-messages. The therapist will devote about 10 minutes to each participant each week via the Internet. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment etc.
Study: NCT01051726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy oil
Description: Oil consists of Clary Sage, Peppermint, Lavender and Frankincense with drops of each mixed into a carrier oil.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: None essential oil
Description: Baby oil
Study: NCT03923049

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: hybrid PET/MRI
Description: On the day of the procedure, subjects will undergo a PET scan followed by MRI scan.
Study: NCT04467892

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ventilators
Description: all patients in both groups will be ventilated with CMV for 2 weeks
Study: NCT03866629

Intervention type: DRUG
Intervention: Lifitegrast
Description: Lifitegrast ophthalmic solution 5%
Study: NCT03246061

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intracept System
Description: BVN ablation using radiofrequency energy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Non-surgical standard care
Study: NCT00914082

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self hypnosis
Description: 3 antenatal classes of 1 hour. 3 audio compact discs for reenforcement. 1 audio compact discs for support at birth

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self hypnosis
Description: 3 antenatal classes of 1 hour. 3 audio compact discs for reenforcement. 1 audio compact discs for support at birth

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self hypnosis
Description: 3 antenatal classes of 1 hour. 3 audio compact discs for reenforcement. 1 audio compact discs for support at birth
Study: NCT01456546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proguanil
Description: 2x350 mg Malarone followed by 3 days of blood- and urine sampling

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 2x300 mg Plavix followed by 7 hours days of blood sampling
Study: NCT01599481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Career Management (ICM)
Description: The intervention will be Individual Career Management (ICM) support for a six month period. ICM consists of individually tailored support to help an individual to obtain and retain in employment. ICM follows the seven principles of supported employment (often referred to an Individual Placement and Support), but includes the additional principles of career counselling, motivational coaching, education and training support, and specialist job retention support. The length and frequency of ICM support sessions is determined by the needs of the client.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: A package of psychological therapy delivered by an Improving Access to Psychological Therapies (IAPT) practitioner.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: A package of psychological therapy delivered by an Improving Access to Psychological Therapies (IAPT) practitioner.
Study: NCT02983253

Intervention type: OTHER
Intervention: blood sample
Description: none, only laboratory tests on blood serum

Intervention type: OTHER
Intervention: blood sample
Description: none, only laboratory tests on blood serum
Study: NCT03282591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Serlopitant Tablets
Description: Serlopitant Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Tablets
Description: Placebo Tablets
Study: NCT01872806

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: a dialing smartphone will be placed on the chest and the ear
Study: NCT02436499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin-A
Study: NCT00967083

Intervention type: BEHAVIORAL
Intervention: Questionnaires/Interviews
Description: Baseline assessment of distressed caregivers within 4-6 weeks a new visit to the thoracic clinic. Three-month follow-up assessment of caregivers. Qualitative phone interviews with a subsample of 30 caregivers within 3 weeks of follow-up.
Study: NCT00463489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Women randomized to the lifestyle intervention arm will receive an intervention program that consists of individual weight loss, diet and physical activity goals, incorporated into a 2 year standardized, structured telephone and mail-based intervention. In addition to diet and physical activity, the intervention will address behavioural and motivational issues relating to weight management including maintaining motivation, overcoming obstacles to success, relapse prevention, emotional distress, stress and time management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mail-based
Description: Participants will receive a standardized mail-based intervention focussing on healthy living. This will include mailings at study entry as well as a two year subscription to health magazine.
Study: NCT03126110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.
Study: NCT03748368

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cataract presentation
Description: Presentation about cataract surgery
Study: NCT03126110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.
Study: NCT03614806

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Simultaneous Transcutaneous and End-tidal CO2 measurements
Description: Included patients will be invited to fill in the Nijmegen questionnaire. During the hyperventilation test, PtcCO2 (mmHg) will be recorded simultaneously with the standard End-tidal Cpartial pressure CO2 measurement
Study: NCT00980746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral route
Study: NCT04344951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UNIKINON (Chloroquine phosphate) 200mg tablets
Description: Two and a half tablets (500mg) twice daily for seven days.
Study: NCT02323568

Intervention type: OTHER
Group type: OTHER
Intervention: Gynecological consultation
Study: NCT01322737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Access and Resection System
Description: This feasibility trial will assess the effectiveness of SuMO System to create a submucosal pocket and resect the overlying mucosa in excised human colonic or gastric tissue
Study: NCT02926287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambulatory surgery
Description: All patients who accepting participation to the study and operated for prolapse surgery, Patient eligible for Ambulatory surgery and return home on the same day if delivery criteria are satisfied ( Chung criteria+tsuccessful trial of void) Patient not eligible for Ambulatory surgery are included as control group
Study: NCT02816359

Intervention type: OTHER
Group type: OTHER
Intervention: head-bed position
Description: Head-bed position at 0° for 30 minutes then head-bed position at 30° for 30 minutes
Study: NCT03058393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teach-Back Lesson
Description: A teach-back lesson will be given to providers (teach-back group) who have challenging clinical discussions with patients
Study: NCT02595320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be given to participants in Arm A at 1500 mg PO BID for 7 days, followed by a 7 day rest (7-7).~Capecitabine will be given to participants in group B at 1250 mg/m2 OR 1000 mg/m2 PO BID for 14 days, followed by a 7 day rest (14-7).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine will be given to participants in Arm A at 1500 mg PO BID for 7 days, followed by a 7 day rest (7-7).~Capecitabine will be given to participants in group B at 1250 mg/m2 OR 1000 mg/m2 PO BID for 14 days, followed by a 7 day rest (14-7).
Study: NCT04375553

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Intradialytic aerobic exercise
Study: NCT02418936

Intervention type: DEVICE
Intervention: gene diagnostic kit

Intervention type: DEVICE
Intervention: gene diagnostic kit
Study: NCT03747406

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: the level between T9 and T10 will be identified using ultrasound as well as transverse processes depth. An array probe will be applied longitudinal orientation 3 cm lateral midline. The erector spinae and the psoas muscle will be identified. A skin wheal will be made using lidocaine 1% at each level and then a 22-gauge Tuohy needle will be advanced inplane until it made contact with the transverse process. The needle will be withdrawn slightly and 30cc of bupivacaine 0.25 % (15ml for each side) will be injected slowly after negative aspiration was confirmed. The same procedure will be repeated in the contralateral side.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: a linear array transducer 5-12 MHz will be positioned inferior and parallel to the costal margin in a medio-lateral orientation. The external oblique, internal oblique and transverse abdominis muscles will be identified immediately lateral to the linea semilunaris. A a 22-gauge needle will be advanced medially and in-plane to the US beam until the tip lies between the fascia of the internal oblique muscle and the transverse abdominis muscle layers. 30 ml of 0.25 % bupivacaine will be injected in each side and the spread will be observed between the two muscles layers.
Study: NCT03748368

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo presentation
Description: Presentation about the history of the hospital
Study: NCT02020837

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphaticovenous Micro-Anastomosis
Study: NCT01198535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study: NCT00335751

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography computed tomography (PET/CT)
Description: The first PET/CT scan will be performed as part of clinical evaluation of sarcoma; The second PET/CT scan will be performed 6 weeks after the start of chemotherapy treatment OR 6 weeks after the end of radiation therapy, to monitor response of sarcoma to treatment.